Gu Wei-ying, Chen Zi-xing, Cao Xiang-shan, Hu Shao-yan, Zhu Jiang, Wang Zhi-lin, Yan Feng, Wang Wei, Cen Jian-nong, Shen Hui-ling, Qian Jun
The First Affiliated Hospital of Soochow University, Jiangsu Institute of Hematology, Suzhou 215006, China.
Zhonghua Xue Ye Xue Za Zhi. 2004 Dec;25(12):728-31.
To investigate Wilms' tumor gene (WT1) expression levels in bone marrow (BM) of acute leukemia patients (ALs).
A real-time quantitative reverse transcriptase polymerase chain reaction (RQ-RT-PCR) method was established for detecting WT1 and internal reference GAPDH expression levels in BM of 108 ALs and 23 non-leukemia controls by Light Cycler.
The median expression levels of WT1 in 70 newly diagnosed ALs and 11 relapsed ALs were statistically higher than those in 23 ALs in complete remission (CR) and 23 non-leukemic controls (75.10 and 89.56 vs 2.07 and 1.51 respectively). No statistic differences was found between the CR group and control group, nor between the newly diagnosed group and relapsed group. Of the 70 newly diagnosed ALs, median WT1 expression level of acute granulocytic leukemias was significantly higher than that of acute monocytic leukemias (M(5)), but there was no statistic differences among the M(1), M(2), M(3) and ALL subtypes. Furthermore the WT1 levels were not correlated to peripheral WBC counts, BM blast percentage and multidrug resistant gene (mdr1) expression at presentation, but correlated to chromosome karyotypes. Dynamic analysis of WT1 levels of 2 patients on treatment showed that WT1 expression levels predicted relapse.
WT1 expression levels in ALs were strikingly higher than that in non-leukemias. WT1 can be a marker for detecting MRD and evaluating therapy efficacy in leukemias.
研究急性白血病患者（ALs）骨髓（BM）中威尔姆斯瘤基因（WT1）的表达水平。
建立实时定量逆转录聚合酶链反应（RQ-RT-PCR）方法，采用Light Cycler检测108例急性白血病患者和23例非白血病对照者骨髓中WT1及内参甘油醛-3-磷酸脱氢酶（GAPDH）的表达水平。
70例初诊急性白血病患者和11例复发急性白血病患者WT1的中位表达水平显著高于23例完全缓解（CR）的急性白血病患者及23例非白血病对照者（分别为75.10和89.56，对比2.07和1.51）。CR组与对照组之间、初诊组与复发组之间均无统计学差异。70例初诊急性白血病患者中，急性粒细胞白血病WT1的中位表达水平显著高于急性单核细胞白血病（M(5)），但M(1)、M(2)、M(3)及急性淋巴细胞白血病（ALL）各亚型之间无统计学差异。此外，WT1水平与初诊时外周血白细胞计数、骨髓原始细胞百分比及多药耐药基因（mdr1）表达无关，但与染色体核型有关。对2例治疗中的患者WT1水平进行动态分析显示，WT1表达水平可预测复发。
急性白血病患者WT1表达水平显著高于非白血病患者。WT1可作为检测白血病微小残留病（MRD）及评估治疗疗效的标志物。
